Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Sep 14, 2023
Vascular Tickers $ANGO, $AORT, $LMAT, $AKBA, and $AVGR Surge +252.11% in a Single Day

Vascular Tickers $ANGO, $AORT, $LMAT, $AKBA, and $AVGR Surge +252.11% in a Single Day

 

The Vascular group of tickers has recently made waves by recording a staggering +252.11% increase in performance over just one day. This remarkable surge has garnered significant attention from investors and traders alike, prompting a closer examination of the theme and the individual tickers within it.

Vascular Tickers in Focus: $ANGO$AORT$LMAT$AKBA and $AVGR

The Vascular theme is represented by a group of five tickers: ANGO, AORT, LMAT, AKBA, and AVGR. These companies operate in the vascular industry, which encompasses a wide range of medical and healthcare-related activities. While this theme has recently experienced a surge in performance, it's essential to consider both short-term and long-term factors when evaluating investment opportunities within this sector.

Negative Outlook with Bearish Predictions

Despite the recent surge, Tickeron, a prominent market prediction source, has a negative outlook on this group of vascular tickers. Tickeron predicts a potential decline of more than 4.00% within the next month, with a likelihood of 61%. This bearish forecast suggests that investors should exercise caution and conduct thorough research before considering investments in these stocks.

Volume Trends and Market Sentiment

Analyzing volume trends can provide valuable insights into market sentiment. Over the last month, the daily ratio of advancing to declining volumes in the vascular theme was 1 to 1.18. This indicates that there has been a balance between buying and selling activity within this sector, contributing to the recent price surge.

Market Capitalization Diversity

The market capitalization of companies within the vascular theme varies significantly. On average, these companies have a market capitalization of approximately $490.6 million. Among the five tickers in focus, LMAT holds the highest valuation, with a market capitalization of $1.3 billion. In contrast, AVGR is the lowest valued company in this group, with a market capitalization of only $4.6 million. This wide range of market caps within the theme highlights the diversity of investment opportunities available in the vascular sector.

Price Performance and Notable News

The price performance of vascular-related stocks has been nothing short of spectacular in the short term. On a weekly basis, the average price growth across all stocks in this theme was an astonishing 200.28%, indicating rapid gains. The average monthly and quarterly price growth figures were equally impressive, standing at 140.05% and 107.46%, respectively. However, it's important to note that these figures represent short-term volatility.

Individual Ticker Analysis

Let's take a closer look at three of the key tickers within this theme:

  1. ANGO: The Aroon Indicator for ANGO entered a downward trend on August 18, 2023. This bearish signal, combined with historical patterns, suggests a potential downward move. Traders may consider selling the stock or buying put options. While ANGO has experienced recent challenges, the stock fell by just 1% during the week of 09/05/23 - 09/12/23.

  2. AORT: AORT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 05, 2023. This bearish signal indicates a possible decline ahead. Historical data shows that in 84% of similar instances, the stock moved lower after such a signal. While AORT experienced a recent -1% decline during the week of 09/05/23 - 09/12/23, it's important to monitor its performance closely.

  3. LMAT: LMAT's MACD Histogram turned positive on August 23, 2023, signaling a potential upward trend. Historical data suggests that in 78% of similar instances, the stock continued to rise over the following month. LMAT has enjoyed a +3% uptrend during the week of 09/05/23 - 09/12/23, and its current price is above the highest support line found by A.I.

In summary, the recent surge in performance within the Vascular theme has been exceptional, but it's crucial for investors to approach this sector with caution due to the negative outlook and bearish predictions. While there are opportunities for short-term gains, the long-term stability of these stocks should be carefully considered. As with any investment, thorough research and risk assessment are essential before making decisions in the ever-changing world of financial markets.

Related Ticker: AVGR, AKBA, AORT, ANGO, LMAT

Contributor

Dem Sem's AvatarDem Sem|Expert

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of catheter devices used to treat vascular diseases

Industry MedicalSpecialties

Profile
Details
Industry
Medical Specialties
Address
400 Chesapeake Drive
Phone
+1 650 241-7900
Employees
72
Web
https://avinger.com
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.